PURPOSE: To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT). METHODS AND MATERIALS: Adult patients aged <70 years with biopsy-proven GBM were treated with SDRT (60 Gy at 2 Gy per fraction) or with HDRT (>60 Gy) and TMZ from 2000 to 2012. Biological equivalent dose at 2-Gy fractions was calculated for the HDRT assuming an α/β ratio of 5.6 for GBM. RESULTS: Eighty-one patients received SDRT, and 128 patients received HDRT with a median (range) biological equivalent dose at 2-Gy fractions of 64 Gy (61-76 Gy). Overall median follow-up time was 1.10 years, and for living patients it was 2.97 years. Actuarial 5-year overall survival (OS) and progression-free survival (PFS) rates for patients that received HDRT versus SDRT were 12.4% versus 13.2% (P=.71), and 5.6% versus 4.1% (P=.54), respectively. Age (P=.001) and gross total/near-total resection (GTR/NTR) (P=.001) were significantly associated with PFS on multivariate analysis. Younger age (P<.0001), GTR/NTR (P<.0001), and Karnofsky performance status ≥80 (P=.001) were associated with improved OS. On subset analyses, HDRT failed to improve PFS or OS for those aged <50 years or those who had GTR/NTR. CONCLUSION: Moderate radiation therapy dose escalation above 60 Gy with concurrent TMZ does not seem to improve clinical outcomes for patients with GBM.
PURPOSE: To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT). METHODS AND MATERIALS: Adult patients aged <70 years with biopsy-proven GBM were treated with SDRT (60 Gy at 2 Gy per fraction) or with HDRT (>60 Gy) and TMZ from 2000 to 2012. Biological equivalent dose at 2-Gy fractions was calculated for the HDRT assuming an α/β ratio of 5.6 for GBM. RESULTS: Eighty-one patients received SDRT, and 128 patients received HDRT with a median (range) biological equivalent dose at 2-Gy fractions of 64 Gy (61-76 Gy). Overall median follow-up time was 1.10 years, and for living patients it was 2.97 years. Actuarial 5-year overall survival (OS) and progression-free survival (PFS) rates for patients that received HDRT versus SDRT were 12.4% versus 13.2% (P=.71), and 5.6% versus 4.1% (P=.54), respectively. Age (P=.001) and gross total/near-total resection (GTR/NTR) (P=.001) were significantly associated with PFS on multivariate analysis. Younger age (P<.0001), GTR/NTR (P<.0001), and Karnofsky performance status ≥80 (P=.001) were associated with improved OS. On subset analyses, HDRT failed to improve PFS or OS for those aged <50 years or those who had GTR/NTR. CONCLUSION: Moderate radiation therapy dose escalation above 60 Gy with concurrent TMZ does not seem to improve clinical outcomes for patients with GBM.
Authors: A Zygogianni; M Protopapa; A Kougioumtzopoulou; F Simopoulou; S Nikoloudi; V Kouloulias Journal: Clin Transl Oncol Date: 2018-01-15 Impact factor: 3.405
Authors: Satoka Shidoh; Ricky R Savjani; Nicholas S Cho; Henrik E Ullman; Akifumi Hagiwara; Catalina Raymond; Albert Lai; Phionah L Nghiemphu; Linda M Liau; Whitney B Pope; Timothy F Cloughesy; Tania B Kaprealian; Noriko Salamon; Benjamin M Ellingson Journal: J Neurooncol Date: 2022-09-02 Impact factor: 4.506
Authors: Carole Grasso; Marie-Sophie Fabre; Sarah V Collis; M Leticia Castro; Cameron S Field; Nanette Schleich; Melanie J McConnell; Patries M Herst Journal: Front Oncol Date: 2014-12-15 Impact factor: 6.244
Authors: David Y A Dadey; Vaishali Kapoor; Arpine Khudanyan; Fumihiko Urano; Albert H Kim; Dinesh Thotala; Dennis E Hallahan Journal: Oncotarget Date: 2016-01-12
Authors: Giovanni Borasi; Alan Nahum; Margarethus M Paulides; Gibin Powathil; Giorgio Russo; Laura Fariselli; Debora Lamia; Roberta Cirincione; Giusi Irma Forte; Cristian Borrazzo; Barbara Caccia; Elisabetta di Castro; Silvia Pozzi; Maria Carla Gilardi Journal: J Ther Ultrasound Date: 2016-12-08
Authors: Qi Liu; Luis Palomero; Jade Moore; Ines Guix; Roderic Espín; Alvaro Aytés; Jian-Hua Mao; Amanda G Paulovich; Jeffrey R Whiteaker; Richard G Ivey; George Iliakis; Daxian Luo; Anthony J Chalmers; John Murnane; Miquel Angel Pujana; Mary Helen Barcellos-Hoff Journal: Sci Transl Med Date: 2021-02-10 Impact factor: 17.956
Authors: Maximilian Niyazi; Patrick N Harter; Elke Hattingen; Maya Rottler; Louisa von Baumgarten; Martin Proescholdt; Claus Belka; Kirsten Lauber; Michel Mittelbronn Journal: Oncotarget Date: 2016-01-19
Authors: Paolo Tini; Valerio Nardone; Pierpaolo Pastina; Giuseppe Battaglia; Clelia Miracco; Lucio Sebaste; Giovanni Rubino; Alfonso Cerase; Luigi Pirtoli Journal: Biomed Res Int Date: 2017-10-12 Impact factor: 3.411